The present disclosure provides novel compounds derived from docosahexaenoic acid endocamabinoid epoxides having anti-cancer, anti-inflammatory, anti-platelet aggregation and anti-angiogenic properties. Methods of synthesizing and using the compositions are also provided.

The present disclosure provides chemical compound derivatives of a class of biological lipid mediators known as endocannabinoids and methods of synthesizing the compositions. These compounds are useful for treating cancer, reducing inflammation, reducing platelet aggregation, and reducing angiogenesis.

The present disclosure provides chemical compound derivatives of a class of biological lipid mediators known as endocannabinoids and methods of synthesizing the compositions. These compounds are useful for treating cancer, reducing inflammation, reducing platelet aggregation, and reducing angiogenesis.

The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.

The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.

Disclosed are compounds of formulae: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

##STR00001##

Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

##STR00001##

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II):

##STR00001##

or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor.

The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II):

##STR00001##

or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, modulation of 5-hydroxytryptamine (5-HT) receptor subtypes, including 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor, and treatment of a condition or disease where the treatment is associated with the modulation of 5-hydroxytryptamine 2A receptor and/or 5-hydroxytryptamine 2C receptor.